Journal article

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson Show all

ANNALS OF NEUROLOGY | WILEY | Published : 2015

Grants

Awarded by Multiple Sclerosis Research Australia Postdoctoral Fellowship


Awarded by National Health and Medical Research Council (NHMRC) Early Career Fellowship


Awarded by NHMRC Career Development Award


Awarded by NHMRC


Awarded by NHMRC Centre for Research Excellence


Awarded by Charles University in Prague Project Grant


Awarded by Czech Ministry of Health Project Grant


Funding Acknowledgements

This work was supported by the Multiple Sclerosis Research Australia Postdoctoral Fellowship (11-054, to T.K.), National Health and Medical Research Council (NHMRC) Early Career Fellowship (1071124, to T.K.), NHMRC Career Development Award (628856, to H.B.), NHMRC Project Grant (1032484, to H.B.), NHMRC Centre for Research Excellence (1001216, to H.B.), and MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer Schering, Sanofi-Aventis, and BioCSL. D.H. and E.H. are recipients of the Charles University in Prague Project Grant (PRVOUK-P26/LF1/4) and Czech Ministry of Health Project Grant (NT13237-4/2012).